MARY ORIANS: Open Payments
NPI 1093741449 · ROSEBURG, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$882 in 30 payments from 17 companies in 2025. Trend: 2023 $91 · 2024 $374 · 2025 $882
Food & beverage: $866Education: $16
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $185 |
| Axsome Therapeutics, Inc. | 3 | $155 |
| ABBVIE INC. | 5 | $125 |
| Novo Nordisk Inc | 2 | $51 |
| REVANCE THERAPEUTICS, INC. | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Edwards Lifesciences Corporation | 1 | $35 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| Amgen Inc. | 1 | $32 |
| Exact Sciences Corporation | 1 | $31 |
Products named: Auvelity, FARXIGA, UBRELVY, DAXXIFY, VRAYLAR, REXULTI, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, TRELEGY ELLIPTA.
Industry payments across OR — which companies pay providers there.
